Navigation Links
Study Pinpoints New Gene for Cystic Fibrosis
Date:2/25/2009

Variant can affect disease severity, experts say,,

WEDNESDAY, Feb. 25 (HealthDay News) -- Researchers have identified a new gene associated with cystic fibrosis.

Dr. Christopher Karp, of the Cincinnati Children's Hospital Medical Center, and an international team of colleagues demonstrated that variants in a gene called IFRD1 can modulate the airway disease that marks cystic fibrosis (CF) by muting the pro-inflammatory activities of white blood cells called neutrophils.

Crucial in clearing bacterial infections, neutrophils have long been suspects in CF airway disease, Karp said. It was thought that they damage the airway via a hyperactive response to the persistent bacterial infections that plague people with CF.

"I think the significance of the paper is it further strengthens the importance of neutrophil function in modulating disease severity," said Chris Penland, director of research at the Cystic Fibrosis Foundation, which partially funded the study.

Though it's too early to recommend changes in genetic screening or counseling, the findings do implicate IFRD1 in particular, and neutrophil activation in general, as potential targets for drug development.

The results were published online Feb. 25 in Nature.

Researchers have long known that mutations in the gene CFTR were associated with cystic fibrosis, but were unable to account for the spectrum of lung disease severity that accompanies the disease.

That, Karp said, suggested two possibilities: "Either that there are strong environmental influences, and/or there are other genes that modify the expression of lung disease in cystic fibrosis."

A handful of modifiers had already been identified, all related to immune cell function. To identify additional candidates, Karp and his team scanned 100,000 genetic markers, called single nucleotide polymorphisms, across the genomes of two large cohorts of people with CF, looking for markers that segregated with airway disease severity. Of the six genetic variations that emerged, the most promising was IFRD1, which coincidentally is located relatively close to the CFTR gene.

IFRD1 is a transcription factor, a protein that regulates the expression of other genes. Karp said they found that the gene is highly expressed in neutrophils, and that neutrophils from mice that lack IFRD1 are less adept at carrying out their antibacterial activities, both in cultures and in animals. Yet at the same time, these mice also suffer less airway damage, weight loss and inflammation from those infections.

"Since we think in the CF airway that neutrophils are basically double-edged swords, and do help against infection but over time destroy the airway, it's a profoundly interesting phenotype," Karp said.

But that's in mice. Does IFRD1 status affect neutrophil function in humans, too?

By assaying human neutrophils, Karp found that in fact it does. That, says Karp, "[closes] the circle, basically."

Thus, the data suggest that subtle variations in the IFRD1 gene modulate neutrophil activity, which can in turn temper the degree of lung damage these cells cause in CF airways.

"This is an interesting finding that might explain why some CF patients have more severe lung deterioration than matched CF [patients] with the same [CFTR] genotype," said Dr. Robert Giusti, director of the Cystic Fibrosis Center at the Long Island College Hospital in Brooklyn, N.Y.

Giusti said the study could eventually pave the way to altered CF management.

"We might be able, by testing for the presence of these modifier genes, to alter our therapy and be more aggressive in the face of a lot of inflammation," he said. "And if we know that a patient is predisposed to inflammation, we can start early on with anti-inflammatory therapy and that might, therefore, limit the degree of lung disease."

However, Karp cautioned that the data do not yet support changing clinical practice.

"Until we get a better sense of what all the modifiers are and how they interact, the field is just not advanced enough," he said.

Researchers must first figure out how IFRD1 fits into the constellation of known and unknown CF gene modifiers and how it carries out its functions on a molecular level.

The study could drive new drug development, however, both at the level of IFRD1 itself and, more generally, at the level of neutrophil activity. In fact, Karp noted that the second most promising genetic location his team identified lies between two other genes also implicated in neutrophil development.

Though the data might not yet support a major drug development effort, Penland stressed that it is clear that people with CF need therapies that treat the underlying disease processes, not just provide symptom relief. "Therefore, what you would in the end have is patients who may die with CF rather than dying from CF," he said.

According to the Cystic Fibrosis Foundation, CF affects about 30,000 people in the United States and 70,000 worldwide.

More information

The Cystic Fibrosis Foundation has more on cystic fibrosis.



SOURCES: Christopher Karp, M.D., Gunnar Esiason/Cincinnati Bell chairman and director, Division of Molecular Immunology, and director, Cystic Fibrosis Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati; Chris Penland, Ph.D., director, research, Cystic Fibrosis Foundation, Bethesda, Md.; Robert Giusti, M.D., chief, pediatric pulmonology, and director, Cystic Fibrosis Center, Long Island College Hospital, Brooklyn, N.Y.; Feb. 25, 2009, Nature, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study analyzes 2006 California heat waves substantial effect on morbidity
2. Study Shows Simple Measures May Help Prevent Sudden Death Event in Young Athletes
3. Million women study shows even moderate alcohol consumption associated with increased cancer risk
4. Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain
5. National Lessons from State Health Reform: The Massachusetts Case Study
6. PSA Tests Not Race-Specific, Study Finds
7. New Texas Study Reveals Serious Flaws in Abstinence Programs
8. U of Minnesota study finds confidence in food safety plunges in wake of peanut butter contamination
9. Update on Landmark Study on Single-Payer as Economic Stimulus
10. Transcendental Meditation buffers students against college stress: Study
11. UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Pinpoints New Gene for Cystic Fibrosis
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... their ongoing community involvement program, introduces a new charity campaign to raise funds ... are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) ...
(Date:2/11/2016)... ... 2016 , ... From March 4 through 6, Hidrex ... at the Walter E. Washington Convention Center in Washington, D.C. , At the ... hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will be talking ...
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... ... ... Early this week, Team Iconic at J. Walter Thompson and Nestlé KITKAT ... global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa Plan aims ... activities that focus on better farming, better lives and better cocoa. In order to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial ... 31, 2015. --> --> Revenue ... $69.1 million in the fourth quarter of 2014, an increase of ... compared with the same period in the prior year. ... in the fourth quarter of 2015, an increase of 9 percent ...
(Date:2/10/2016)... HERTFORDSHIRE, England och ... -- Erbjudandet lämnas inte, och detta ... eller indirekt, i eller till, och inga ... uppdrag av aktieägare i, något land där ... av accept av Erbjudandet skulle strida mot ...
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
Breaking Medicine Technology: